Navigation Links
Cynosure Added to the S&P SmallCap 600 Index
Date:5/31/2013

WESTFORD, Mass., May 31, 2013 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that its stock will be added to the S&P SmallCap 600® Index as of the close of trading today.

"We are pleased to have been selected as a member of the prestigious S&P SmallCap 600 Index, an achievement that is consistent with our focus on delivering long-term value for shareholders through industry leadership and consistent, profitable growth,"  said Michael Davin , Cynosure's president and chief executive officer. "Because a number of funds track the S&P Dow Jones Indices, inclusion in the S&P SmallCap 600 creates an additional opportunity to increase our visibility and broaden our investor base."Introduced in 1994, the S&P SmallCap 600 is fast becoming the preferred small cap index in the U.S., covering approximately 3% of the domestic equities market. The index is designed to be an efficient portfolio of companies that meet specific inclusion criteria to ensure that they are investable and financially viable. Criteria include U.S. company status, market capitalization in the range of $300 million to $1.4 billion, a public float of at least 50%, financial viability, adequate liquidity and reasonable price and sector representation. Complete details on the guidelines for maintaining the index are available at www.standardandpoors.com.

About S&P Dow Jones Indices
S&P Dow Jones Indices LLC, a subsidiary of The McGraw-Hill Companies, is the world's largest, global resource for index-based concepts, data and research. Home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial AverageSM, S&P Dow Jones Indices LLC has over 115 years of experience constructing innovative and transparent solutions that fulfill the needs of institutional and retail investors. More assets are invested in products based upon our indices than any other provider in the world. With over 830,000 indices covering a wide range of assets classes across the globe, S&P Dow Jones Indices LLC defines the way investors measure and trade the markets. To learn more about our company, please visit www.spdji.com.

About Cynosure, Inc.Cynosure develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, visit Cynosure's website at www.cynosure.com.

Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, Cynosure's ability to maintain its profitability, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.Contacts: Timothy BakerScott SolomonExecutive VP, Treasurer and CFOVice President Cynosure, Inc. Sharon Merrill 978.256.4200617.542.5300TBaker@cynosure.comCYNO@investorrelations.com 


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
9. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
10. Cynosure Reports First-Quarter 2013 Financial Results
11. Cynosure to Present at UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... across 154 pages, profiling 09 key companies and ... a professional and in-depth study on the current ... basic overview of the industry including definitions, classifications, ... market analysis is provided for the international market ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... The joy associated with Mother’s Day is mixed with worry and fear for new mothers ... the country. For the first time ever, the March of Dimes and ... Mother’s Day beside a crib surrounded by lifesaving equipment or peering through a glass window ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... ... , ... From the Speaker Podium to the Exhibit Floor at Booth#514, Worldwide ... managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 at the Omni ... Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction in your Contact ...
(Date:5/6/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article ... Bible about helping to stop cancer. Yisrayl says there are too many suffering and dying ... and science industries will pay close attention and take action. The Pastor says that the ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations ... accounts of dying patients who have allowed those holding vigil to glimpse into the ... BSN, CHPN, hopes to help readers spiritually and practically gain insight into providing care ...
Breaking Medicine News(10 mins):